MedPath

Safety and Efficacy of the HA-based Dermal Fillers HYAcorp Lips and Face

Completed
Conditions
Dermal Filler
Interventions
Device: HYAcorp Lips and HYAcorp Face
Registration Number
NCT04546516
Lead Sponsor
BioSCIENCE GmbH
Brief Summary

Purpose of this study is the demonstration of safety and efficacy of the dermal fillers HYAcorp Lips and HYAcorp Face for restoration of the facial volume and contour.

Detailed Description

This is a prospective, multicenter, observational, open label, two-arm, crossover, PMCF clinical trial for demonstration of the safety and efficacy of the HA-based dermal fillers HYAcorp Lips and HYAcorp Face for restoration of the facial volume and contour. Besides safety aspects, evaluated immediately after the treatment, 4 weeks, 3 and 6 months after the treatment, the performance of the demal fillers are evaluated in the 3 and 6 months follow-up by using GAIS and WSRS.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
167
Inclusion Criteria
  • subjects intended for the treatment with HYAcorp Lips and/or Face according to the instructions for use of the product
  • decision for the treatment with HYAcorp Lips and/or Face was made before the subject was recruited for the clinical trial
  • subjects signed written informed consent
  • adult subjects at least 18 years old
  • all Fitzpatrick skin types
  • area treated with one investigational device - no combination of products in one treatment area
Exclusion Criteria
  • tendency to hypertrophic and keloid scarring
  • intolerance to gram-positive bacteria
  • prone to active inflammatory or infectious processes
  • suffering from acute or chronic skin diseases
  • undergoing anti-coagulant therapy
  • known allergy to hyaluronic acid
  • suffering from autoimmune diseases
  • multiple allergies
  • pregnancy or lactating women
  • subjects unlikely to cooperate in the clinical investigation or to comply with the treatment or with the clinical investigation visits

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HYAcorp FaceHYAcorp Lips and HYAcorp FaceHYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
HYAcorp LipsHYAcorp Lips and HYAcorp FaceHYAcorp Lips is indicated for the restoration of volume and contour of the lips.
Primary Outcome Measures
NameTimeMethod
Wrinkle severity assessment 3 months3 months

Wrinkle severity assessment acc. to the Wrinkle Severity Rating Scale (WSRS); 1: wrinkles absent, 2: slight wrinkles, 3: moderate wrinkles, 4: severe wrinkles, 5: very severe wrinkles

Global aesthetic improvement 6 months6 months

Global aesthetic improvement assessment acc. to the Global Aesthetic Improvement Scale (GAIS); 3: very much improved, 2: much improved, 1: improved, 0 unchanged, -1: worse

Wrinkle severity assessment 6 months6 months

Wrinkle severity assessment acc. to the Wrinkle Severity Rating Scale (WSRS); 1: wrinkles absent, 2: slight wrinkles, 3: moderate wrinkles, 4: severe wrinkles, 5: very severe wrinkles

Global aesthetic improvement 3 months3 months

Global aesthetic improvement assessment acc. to the Global Aesthetic Improvement Scale (GAIS); 3: very much improved, 2: much improved, 1: improved, 0 unchanged, -1: worse

Number of subjects with wrinkle severity improvement 3 months3 months

Number of subjects with at least one scale point improvement in the wrinkle severity assessment (WSRS) with respect to baseline

Number of subjects with wrinkle severity improvement 6 months6 months

Number of subjects with at least one scale point improvement in the wrinkle severity assessment (WSRS) with respect to baseline

Secondary Outcome Measures
NameTimeMethod
Product safety 6 months6 months

Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

Product safety immediately after the treatmentImmediately after the treatment

Side effects and adverse event recording; degree of severity: mild, moderate, severe

Product safety 4 weeks4 weeks

Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

Product safety 3 months3 months

Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

Trial Locations

Locations (2)

BioSCIENCE Investigation Site #02

🇩🇪

Kempten, Germany

BioSCIENCE Investigation Site #01

🇩🇪

Bad Honnef, Germany

© Copyright 2025. All Rights Reserved by MedPath